Novo Nordisk stock trades near record territory as Wegovy and Ozempic power earnings growth
Published on 07/20/2026 at 07:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock is supported by a robust earnings trajectory as the Danish healthcare group (ISIN DK0062498333) reports double digit revenue growth driven by obesity and diabetes treatments. In its latest reported full year results for 2023, Novo Nordisk stated that total revenue rose around 31% year on year, underlining how demand for GLP-1 based therapies such as Wegovy and Ozempic is reshaping the company’s financial profile according to its investor materials dated in early February 2024 and subsequent presentations available via its investor relations website.
Revenue up over thirty percent
According to Novo Nordisk’s most recent full year 2023 financial overview available through its investor relations page at Novo Nordisk investor relations, the company reported that total revenue for 2023 increased by approximately 31% compared with 2022, reaching the equivalent of more than DKK 200 billion based on the company’s own currency disclosures. This represents a significant acceleration from the prior year and reflects rapid uptake of its GLP-1 medicines across major markets. The same investor material highlighted that operating profit rose by around 33% year on year in 2023, indicating that profit grew slightly faster than sales as scale effects and a favorable product mix improved margins.
The latest published data from Novo Nordisk’s investor presentations shows that sales in its obesity care segment more than doubled in 2023 versus 2022, with obesity care revenues roughly increasing by more than 100% year on year. This expansion is primarily attributed to Wegovy, the once weekly semaglutide injection approved for weight management, where the company has disclosed that global sales have been scaling rapidly in the United States and selected European markets. The diabetes care franchise also delivered strong growth, with GLP-1 products such as Ozempic and Rybelsus driving mid double digit sales increases relative to the prior year. For investors, the key comparison is that non GLP-1 segments grew at much lower rates, underscoring the central role of GLP-1 therapies in Novo Nordisk’s growth story.
Operating profit growth tops revenue increase
In its full year 2023 reporting, Novo Nordisk emphasized that operating profit expansion outpaced revenue growth, with operating profit up approximately 33% compared with 2022 on a reported basis. That implies a modest improvement in the operating margin as high margin obesity and diabetes treatments contribute a larger share of total sales. The company’s materials for 2023 further indicate that diluted earnings per share rose in the high twenty percent range year on year, reflecting both stronger operating performance and capital allocation measures such as share repurchases and dividends. The quantified comparison between revenue growth of around 31% and operating profit growth of about 33% suggests that Novo Nordisk not only expanded its top line but also gained efficiency and pricing power.
Novo Nordisk’s investor communications for 2023 and early 2024 also outline guidance parameters for the subsequent year, where the company indicated expectations for continued double digit sales growth based on sustained demand for its GLP-1 pipeline and capacity expansions. While precise guidance ranges vary between reported numbers in constant currency and reported currency, the visible pattern is that management continues to target strong growth led by obesity care. The firm has also signaled ongoing investments in manufacturing facilities to alleviate supply constraints that have periodically limited availability of Wegovy in certain geographies, a factor that is important when interpreting the sustainability of reported revenue growth figures.
Novo Nordisk investor information and documents
For more detailed figures, segment breakdowns, and guidance updates, Novo Nordisk provides annual and quarterly reports, investor presentations, and webcasts through its dedicated investor relations portal.
Wegovy and Ozempic drive segment mix
A central reason why Novo Nordisk stock has attracted sustained attention is the performance of its flagship GLP-1 medicines Wegovy and Ozempic. According to the company’s product level disclosures and segment reporting as summarized in its 2023 annual report and subsequent presentations accessed via the investor relations site, GLP-1 products now account for a majority of Novo Nordisk’s diabetes care revenue and an increasingly dominant share of overall group sales. Ozempic, indicated for type 2 diabetes and also prescribed off label for weight management in some markets, delivered strong double digit revenue growth compared with 2022, while Rybelsus, the oral semaglutide tablet, expanded its contribution particularly in markets where oral therapy is preferred.
In obesity care, Wegovy has become a key growth engine. Novo Nordisk’s segment notes indicate that obesity care revenue more than doubled in 2023 versus 2022, with the company benefiting from expanded reimbursement in certain European countries and broader acceptance among physicians and patients. The firm has also highlighted that demand has periodically exceeded supply, leading to phased launches and prioritization strategies, but capacity expansions underway are intended to support continued growth. This context matters for investors analyzing Novo Nordisk stock because it shows that the company’s revenue and profit trajectory is tightly linked to execution in GLP-1 manufacturing and regulatory pathways for obesity treatments.
Beyond GLP-1, Novo Nordisk maintains a diversified portfolio including insulins, other diabetes therapies, and rare disease treatments such as hemophilia products and growth hormone therapies. However, growth in these legacy segments has generally been more modest, and in some cases flat to low single digit, compared with the rapid expansion in GLP-1. As a result, the quantified comparison between GLP-1 segment growth and broader portfolio dynamics underscores a strategic pivot where once central insulin products are now relatively smaller growth contributors. Novo Nordisk has communicated through its investor materials that it continues to invest in next generation insulin and rare disease pipelines, but the near term financial narrative is dominated by GLP-1.
Capital allocation and market capitalization context
Novo Nordisk’s capital allocation policy is another factor underpinning Novo Nordisk stock. The company has a long established practice of paying dividends and conducting share repurchases. In its 2023 financial overview, Novo Nordisk reported total shareholder distributions comprising both cash dividends and buybacks that together amounted to tens of billions of Danish kroner. The company raised its dividend per share in 2023 compared with 2022, continuing a pattern of gradual increases over time, and also executed a sizable share repurchase program that reduced the share count and supported earnings per share growth.
Market data from major exchange portals and financial information providers show that Novo Nordisk’s market capitalization has risen substantially over the past few years as its GLP-1 franchise scaled. As of early 2024, Novo Nordisk was widely reported as one of Europe’s most valuable listed companies, with a market capitalization exceeding the equivalent of $400 billion based on prevailing exchange rates and share prices. This valuation places Novo Nordisk alongside global pharmaceutical and technology giants in terms of equity market size. The magnitude of its market capitalization is a concrete metric reflecting how investors price the earnings trajectory and growth potential of its GLP-1 portfolio.
For investors comparing Novo Nordisk to peers, the contrast in growth rates is stark. Many large pharmaceutical groups report low to mid single digit revenue growth, whereas Novo Nordisk’s reported revenue growth of around 31% in 2023 stands materially higher. This quantified comparison highlights that Novo Nordisk’s current valuation premium is anchored in expectations of sustained GLP-1 demand, but it also implies that any changes in regulatory, competitive, or reimbursement conditions for obesity and diabetes treatments could have outsized effects on future earnings and, by extension, Novo Nordisk stock. As a result, detailed monitoring of clinical data, new product launches, and competitor actions is integral to assessing the company’s long term risk profile.
Wegovy obesity care segment
Wegovy is Novo Nordisk’s leading obesity treatment and plays a central role in the company’s growth outlook. Based on Novo Nordisk’s 2023 segment reporting and product notes accessible via its investor relations information, obesity care revenue more than doubled in 2023 compared with 2022, and Wegovy accounts for most of that segment increase. The company has communicated that it is investing heavily in manufacturing capacity, including new facilities and expansions at existing plants, to increase supply of semaglutide for both Wegovy and Ozempic.
Demand for Wegovy has been driven by clinical evidence showing significant weight loss in patients and growing acceptance of pharmacological solutions for obesity. Novo Nordisk’s materials emphasize that obesity is a major global health challenge, and the company positions Wegovy as part of a broader strategy to combat obesity related comorbidities such as cardiovascular disease and type 2 diabetes. The regulatory environment is evolving, with additional indications under investigation, and Novo Nordisk continues to sponsor clinical trials that could further expand the addressable market for Wegovy in the coming years.
Novo Nordisk stock price and listing details
Novo Nordisk stock is primarily listed on Nasdaq Copenhagen, where it trades under the symbol NOVO B. The company also has American Depositary Receipts listed on the New York Stock Exchange, which provide exposure for US based investors, though the primary liquidity remains in Copenhagen. Recent quote pages from major exchange portals indicate that the share price has been trading close to record highs reached in 2023 and 2024, reflecting the strong earnings and revenue performance discussed above. While precise intraday levels fluctuate, the broader picture is that Novo Nordisk shares have appreciated significantly over the past three years in tandem with the acceleration of GLP-1 demand.
The pricing of Novo Nordisk stock on Nasdaq Copenhagen is quoted in Danish kroner, and the ADRs on the New York Stock Exchange are quoted in US dollars. Investors sometimes compare the share price to historical ranges, including 52-week highs and lows, to gauge volatility and trend strength. Market data show that Novo Nordisk’s shares have moved sharply higher compared with levels three to five years ago, producing substantial total returns for long term holders when dividends are included. This performance, combined with the company’s robust balance sheet and high profitability, contributes to its status as a core holding in many European and global healthcare indices.
Novo Nordisk fundamentals and listing
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NASDAQ Copenhagen: NOVO B
- Trading venue: Nasdaq Copenhagen
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: OMX Copenhagen 25 and widely held in global health care indices
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
